C4 Therapeutics (NASDAQ:CCCC) reported updated clinical data from its Phase 1 trial evaluating cemsidomide, an investigational oral molecular glue degrader targeting IKZF1/3, for the treatment of relapsed or refractory multiple myeloma.
US producer prices increased 6.5% in May from a year earlier, the fastest pace since November 2022, and advanced 1.1% from April as the fallout from the Iran war continued to fan inflation pressures. Michael McKee breaks down the data on Bloomberg Television.
Purple Biotech (NASDAQ:PPBT) unveiled new preclinical data for IM1240, its lead T-cell engager candidate utilizing the proprietary CAPTN-3 platform, at the European Association for Cancer Research (EACR) 2026 Congress.
Climb Bio (NASDAQ:CLYM) reported positive initial Phase 1b clinical data for its drug candidate budoprutug, an anti-CD19 monoclonal antibody, which is being developed to treat adults with primary immune thrombocytopenia.
Vera Bradley (NASDAQ:VRA) reported an unexpected rise in profit margins and its first quarterly top-line expansion in over four years, signaling that its comprehensive brand overhaul is beginning to resonate with retail consumers.
Syndax Pharmaceuticals (NASDAQ:SNDX) unveiled a broad array of clinical data reinforcing the therapeutic profile of its approved blood cancer drug, Revuforj, across several distinct mutations and stages of acute leukemia.
Anduril Industries Inc. Chief Executive Officer Brian Schimpf says the company would "absolutely" consider building its next weapons manufacturing hub outside the US. Speaking to Bloomberg News Editor-in-Chief John Micklethwait at Founders Forum in the UK, Schimpf adds "there's a lot of manufacturing talent that exists" across Europe.
UK Business Secretary Peter Kyle reacts to the resignation of Defense Secretary John Healey from Prime Minister Keir Starmer's cabinet. Healey cited the constraints placed on his long-delayed defense investment plan by the chancellor of the exchequer. "All I can say is that we are in a moment in time when we are investing enormously into our defense," Kyle says in an interview with Bloomberg's Lizzy Burden at the Founders Forum event, outside London. "I don't know the circumstances of John's resignation, because I've just heard it the same time you've read it out there."
Silence Therapeutics (NASDAQ:SLN) reported positive follow-up and quality-of-life clinical data for its experimental blood cancer treatment, divesiran, demonstrating a sustained reduction in the medical procedures required to manage the rare disease.
Driven Brands Holdings (NASDAQ:DRVN) reported a rise in profit and revenue for the first quarter of fiscal 2026, supported by robust performance in its quick-lube business even as the company navigates elevated corporate expenses stemming from its recent financial restatements.
Nurix Therapeutics (NASDAQ:NRIX) released updated Phase 1a/b clinical data for its experimental leukemia drug, bexobrutideg, demonstrating sustained efficacy and high response rates across multiple lines of therapy for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
The Lovesac Company (NASDAQ:LOVE) reported a net loss for its fiscal 2027 first quarter, reflecting the persistent operational difficulties home furnishings retailers face as sticky inflation and elevated mortgage rates suppress discretionary consumer spending.
_1419437_640x360_2503300675874-640x360.webp&w=3840&q=75)
_1419412_640x360_2503296067769-640x360.webp&w=3840&q=75)
_1419409_640x360_2503301699643-640x360.webp&w=3840&q=75)
